Shares of Catalyst Pharmaceutical Partners catapulted 76% on 27 August on news the FDA granted breakthrough therapy designation to the Florida specialty pharma's experimental drug Firdapse (amifampridine phosphate), which is under investigation to treat symptoms associated with Lambert-Eaton Myasthenic syndrome (LEMS), a rare autoimmune disease, which results in muscle weakness, particularly in the legs and trunk.
The stock closed at $2.01, a gain of 59 cents, or about 42%.


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

